PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology

BACKGROUND: Approximately 5–10% of unselected breast cancer (BC) patients retain a hereditary predisposition related to a germline mutation in BRCA1/2 genes. The poly-ADP ribose polymerase (PARP)-inhibitors olaparib and talazoparib have been granted marketing authorization by both FDA and EMA for ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Miglietta, Federica, Cinquini, Michela, Dieci, Maria Vittoria, Cortesi, Laura, Criscitiello, Carmen, Montemurro, Filippo, Del Mastro, Lucia, Zambelli, Alberto, Biganzoli, Laura, Levaggi, Alessia, Delle Piane, Chiara, Marchiò, Caterina, Calabrese, Massimo, Fortunato, Lucio, Franco, Pierfrancesco, Meduri, Bruno, Fittipaldo, Veronica Andrea, Gori, Stefania
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663524/
https://www.ncbi.nlm.nih.gov/pubmed/36379199
http://dx.doi.org/10.1016/j.breast.2022.10.014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663524/
https://www.ncbi.nlm.nih.gov/pubmed/36379199
http://dx.doi.org/10.1016/j.breast.2022.10.014

Ejemplares similares